Year: 2024
Type: article
Abstract: Transthyretin amyloidosis (ATTR) is an underdiagnosed and undertreated systemic disease secondary to deposition of mis-folded transthyretin (TTR) proteins, including in the heart and peripheral nerves.Protein misfolding occurs in an autosomal dominant hereditary form, secondary to pathogenic variants in the TTR gene (vATTR) or in the absence of a variant (wild-type ATTR).Previously thought to be a rare disease with limited therapeutic options, recent data have improved our understanding of its not-so-rare prevalence and highlighted the impact of several novel therapies.Coupled with the long latency of most variants, the genetic underpinnings of vATTR imply opportunity for identifying at-risk carriers and early detection of disease.The American College of Medical Genetics guidelines have underscored the importance of TTR variants, which are classified as reportable secondary findings.1 Since late-stage presentation is unfortunately common (including heart failure [HF], conduction system disease, arrhythmias, and neuropathy), 2,3 better screening tools to identify earlier-stage disease seem rational.The availability of targeted therapies, including stabilizer medications, which may be more effective earlier in the disease course, further support early detection, and multiple other targeted therapies, including silencers, antibodies, and gene-editing techniques, are on the horizon.
Source: JAMA Cardiology
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4401948579
